Compositions and methods for targeting interleukin-12 to malignant endothelium
OwnerErin B. Dickerson, Stuart C. Helfandinventors
Life of this patent
Estimating the term…
Abstract
Fusion proteins containing a mammalian interleukin-12 operably linked to a RGD-containing peptide as well as nucleic acid sequences, vectors and host cells for expression of these fusion proteins are provided. Also provided are method of using these fusion proteins to inhibit tumor growth and to decrease the toxicity associated with interleukin-12 administration.
Claims9
A fusion protein comprising a mammalian interleukin-12 operably linked to a RGD-containing peptide.
A method for decreasing toxic side effects associated with interleukin-12 administration in a mammal comprising operatively linking interleukin-12 to a RGD-containing peptide via expression of a fusion protein comprising interleukin-12 and a RGD-containing peptide and administering to the mammal the fusion protein.
A method for treating cancer in a mammal comprising administering to the mammal a fusion protein comprising interleukin-12 operably linked to an RGD-containing peptide.
Dependencies are inferred from the claim text.